Phase III
In honor of March 24, World TB Day, BioSpace looks at clinical trials and eradication efforts occurring today.
AstraZeneca shared that using imfinzi alongside chemoradiotherapy did not meet statistical significance in improving progression-free survival versus using CRT alone.
The U.S. Food and Drug Administration rejected Eli Lilly’s Biologics License Application, issuing a Complete Response Letter for the company’s PD-1 checkpoint inhibitor sintilimab.
The FDA approved Pluvicto (targeted radioligand therapy) for use in adults with PSMA-positive mCRPC that has already metastasized to other body parts.
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
Pfizer is lining up a potential New Drug Application for an ulcerative colitis treatment for patients who are not seeing an improvement in their condition from currently available options.
Neurana Pharmaceuticals is facing dire financial straits following the failure of its Phase III treatment for muscle spasm relief associated with an acute, painful musculoskeletal condition.
Data from the Phase III study showed that efgartigimod achieved the primary endpoint of total IgG reduction from the baseline on the 29th day of observation.
Today, New Jersey-based Tonix announced that TNX-102 SL failed to generate a statistically significant outcome in fibromyalgia patients.
ImmunoGen shares inexplicably plunged 23% after the company announced positive Phase III results of its new ovarian cancer treatment.
PRESS RELEASES